Quantcast

Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases – Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients

March 3, 2010

REHOVOT, Israel, and SAN DIEGO, California, March 3, 2010 /PRNewswire/ –
Foamix Ltd., (Foamix), a leading developer of topical foams for
dermatological and gynecological use, and Therapeutics Inc. (TI), an
innovative drug development company, announced today a joint venture that
will focus on developing new prescription medicated foam formulations and
demonstrating their safety and efficacy.

The partnership will accelerate the development of value-added foam
formulations for the treatment of common skin inflammation conditions, such
as atopic dermatitis and psoriasis, which inflict more than 20 million
Americans, as well as seborrheic dermatitis and allergic skin reactions.

“It is with enthusiastic anticipation that we enter into our partnership
with Therapeutics Inc, a dynamic company that can move promising topical
drugs through preclinical and clinical studies into the marketplace,” said
Dr. Dov Tamarkin, CEO of Foamix. “What we are creating through this joint
venture is a powerful development engine that will leverage our respective
expertise and resources to drive new products to market.”

“Foamix has a proven track record of successfully marrying their
proprietary and unique foam systems with dermatological drugs. Together we
will develop unique Rx foams that can be readily applied to the sensitive
skin of atopic dermatitis and psoriasis patients. These products will fill an
unmet market need for convenient and elegant treatments of inflammatory skin
diseases,” said Daniel Piacquadio, M.D, President & CEO of Therapeutics Inc,
as he announced the joint development agreement.

About Foamix

Foamix Ltd. is a leading developer of topical and mucosal foams for
dermatological and gynecological applications. Foamix’s state-of-the-art
foams provide controlled delivery of a variety of active ingredients. Foamix
is currently collaborating with pharmaceutical and cosmetic companies on a
range of projects in the development of proprietary dermatological and
gynecologic foam products. Additionally, the Company has an in-house pipeline
of dermatological and gynecological formulations in foam presentation.
Foamix’s psoriasis foam product licensed to Dr. Reddy’s Laboratories and
marketed by Promius Pharma under the trade mark Scytera(TM) was launched in
the United States in early 2009.

Foamix has nineteen issued patents worldwide covering its foam and OilGel
technology platforms and over 150 pending applications of which more than 60
are filed in the United States.

About Therapeutics, Inc

Therapeutics, Inc. (TI) is a drug development company focused on
developing innovative treatments for cutaneous and mucosal diseases. TI
provides unwavering service and moves products from concept to the bench top,
to proof-of-concept and then, as appropriate, through clinical development
with regulatory review and approval. TI evaluates and integrates clinical,
regulatory, technology, market and competitive factors to develop
best-of-class dermatology solutions.

    For additional information please see http://www.therapeuticsinc.com

    Media Contact: Denise Dwyer, Therapeutics, Inc.
    Phone: +1-858-571-1800 x106
    E-mail: media@therapeuticsinc.com

    For additional information please see http://www.foamix.co.il

    Media contact: Sigal Maymon, Foamix Ltd.
    Phone: +972-8-9316233
    E-mail: info@foamix.co.il

SOURCE Foamix Ltd


Source: newswire



comments powered by Disqus